CADTH | Evidence Driven
CADTH | Evidence Driven

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in People with Previous Bacille Calmette-Guérin Vaccination: Clinical Utility, Cost-Effectiveness, and Guidelines

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1513-000

Question

  1.  What is the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?
  2. What is the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?
  3. What are the evidence-based guidelines regarding the identification of latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?

Key Message

One non-randomized study was identified regarding the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination. In addition, one evidence-based guideline was regarding the identification of latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination. No relevant economic evaluations were identified regarding the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination.

Files

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in People with Previous Bacille Calmette-Guérin Vaccination: Clinical Utility, Cost-Effectiveness, and Guidelines Rapid Response August 20, 2020 View PDF

Related Content

Last Updated : August 31, 2020